CARLSBAD, Calif.--(BUSINESS WIRE)--As part of its ongoing commitment to support clinical oncology research, Thermo Fisher Scientific is calling for new proposals for its Oncomine Clinical Research Grant. The latest request for submissions from the global scientific community will award funding for molecular profiling research that helps accelerate the use of genomic sequencing in oncology.
The recipients of the grants will each be awarded up to $200,000 in reagents and general funding for independent clinical research proposals that demonstrate excellence in cancer molecular profiling. Project proposals harnessing the value of next generation sequencing (NGS) in either the context of solid or hematological cancers will be reviewed by independent and internationally recognized experts for scientific rigor and merit. Grant proposals are now being accepted through April 7, 2022.
“The Oncomine Clinical Research Grant program aims to fund research furthering our understanding of cancer at the genomic level. The identification of specific cancer biomarkers associated with response or resistance to treatment can inform clinical care and potentially help predict patient outcomes,” said José Luis Costa, Ph.D., director of medical affairs for clinical next-generation sequencing and oncology, Thermo Fisher Scientific. “Thermo Fisher is committed to supporting scientists and researchers globally as we look to advance cutting-edge genetic research.”
Since launching the program in 2020, Thermo Fisher has awarded Oncomine Clinical Research Grants to 16 projects worldwide in support of research in hematology-oncology, immuno-oncology, liquid biopsy, and fusion gene detection. Recipients of the last funding round, which supported clinical research programs using NGS technology in solid tumors and hematology-oncology applications, included: Myung-shin Kim, The Catholic University of Korea Seoul St. Mary’s Hospital, South Korea; Wolfram Jochum, Kantonsspital St. Gallen, Switzerland; Fernando Lopez-Rios, Hospital Universitario 12 de Octubre, Spain; Tarek Bismar, University of Calgary, Canada.
“Next-generation sequencing is vital to match eligible patients with lung carcinomas with targeted therapies, but often this testing takes too long to inform their care,” said grant recipient Fernando Lopez-Rios, Hospital Universitario 12 de Octubre. “With the support from the Oncomine Clinical Research Grant, we hope to demonstrate that comprehensive genomic sequencing with very rapid turnaround times can increase patient access and advance the idea of universal testing of all patients with lung carcinomas, including those with early-stage disease.”
For more information on the Oncomine Clinical Research Grant and how to submit proposals, please visit www.oncomine.com/grants.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.